Abstract
In this issue of Blood, Kolstad et al report an elegantly designed and well-implemented study showing that intratumoral injection of ex vivo-produced immature dendritic cells (DCs), granulocyte macrophage colony-stimulating factor (GM-CSF), and low-dose rituximab into an irradiated tumor elicits objective responses at untreated sites and that these clinical remissions correlate with the induction of tumor-reactive CD8 T-cell responses.
| Original language | English |
|---|---|
| Pages (from-to) | 5-7 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 125 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Jan 2015 |